Scientists at The Scripps Research Institute (TSRI) have given new superpowers to a lifesaving antibiotic called vancomycin, an advance that could eliminate the threat of antibiotic-resistant infections for years to come.
The researchers, led by Dale Boger, co-chair of TSRI’s Department of Chemistry, discovered a way to structurally modify vancomycin to make an already-powerful version of the antibiotic even more potent.
“Doctors could use this modified form of vancomycin without fear of resistance emerging,” said Boger, whose team announced the finding today in the journal Proceedings of the National Academy of Sciences.
The original form of vancomycin is an ideal starting place for developing better antibiotics. The antibiotic has been prescribed by doctors for 60 years, and bacteria are only now developing resistance to it. This suggests bacteria already have a hard time overcoming vancomycin’s original “mechanism of action,” which works by disrupting how bacteria form cell walls.
Boger called vancomycin “magical” for its proven strength against infections, and previous studies by Boger and his colleagues at TSRI had shown that it is possible to add two modifications to vancomycin to make it even more potent. “With these modifications, you need less of the drug to have the same effect,” Boger said.
The new study shows that scientists can make a third modification–which interferes with a bacterium’s cell wall in a new way–with promising results. Combined with the previous modifications, this alteration gives vancomycin a 1,000-fold increase in activity, meaning doctors would need to use less of the antibiotic to fight infection.
The discovery makes this version of vancomycin the first antibiotic to have three independent mechanisms of action. “This increases the durability of this antibiotic,” said Boger. “Organisms just can’t simultaneously work to find a way around three independent mechanisms of action. Even if they found a solution to one of those, the organisms would still be killed by the other two.”
Tested against Enterococci bacteria, the new version of vancomycin killed both vancomycin-resistant Enterococci and the original forms of Enterococci.
The next step in this research is to design a way to synthesize the modified vancomycin using fewer steps in the lab, as the current method takes 30 steps. But Boger calls this the “easy part” of the project, compared with the challenge of designing the molecule in the first place.
Even if the process isn’t streamlined, Boger believes the new vancomycin’s lifesaving powers make its production valuable. “Antibiotics are total cures for bacterial infections,” said Boger. “Making this molecule is important, even by the current approach, if the failure of antibiotics continues.”
The Latest on: Vancomycin
Motif Bio to present new Iclaprim safety and efficacy data at top European conference
on April 19, 2018 at 12:31 am
Data from the trial also showed that iclaprim was just as good as (the technical term is ‘non-inferior to’) the gold standard medication, vancomycin. Having had a few more months to digest and analyse the results further, Motif Bio has expanded on many ... […]
Motif Bio Announces New Iclaprim Data being Presented at ECCMID 2018
on April 18, 2018 at 11:13 pm
Positive efficacy and safety highlights from Phase 3 REVIVE-2 trial in ABSSSI Potential to avoid costs related to vancomycin-associated acute kidney injury in ABSSSI Data continue to support iclaprim activity against MRSA and other drug-resistant pathogens ... […]
Clostridium Difficile Diagnostics and Treatment Market to Surpass US$ 2,576.3 Million Threshold by 2025 Globally
on April 18, 2018 at 1:05 pm
Clostridium difficile infection management includes diagnosis of the infection using various tests and medication therapies using antibiotics such as Vancomycin and Fidaxomicin. Request a sample copy of this report: www.coherentmarketinsights.com/insight ... […]
Study finds incidence and predictors of multiple vancomycin-associated AKI
on April 18, 2018 at 8:19 am
AUSTIN, Texas — A study presented at the National Kidney Foundation Spring Clinical Meetings showed data suggesting patients who had been treated with vancomycin and had acute kidney injury were at an elevated risk of subsequent acute kidney injury when ... […]
ADVENTURES IN FOOD AND FITNESS: Fecal transplants help Fort Wayne patients suffering from deadly diarrhea
on April 16, 2018 at 1:02 am
When Professor Rachel Polando tells her microbiology students at Manchester University about her brother the poop donor, it invariably generates a wisecrack or two. Who knew you could actually get paid for a foul-smelling waste product most humans produce ... […]
via Google News and Bing News